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To the Editor: 
Diabetes and obesity are associated with severe COVID19-associated disease including acute           
respiratory distress syndrome (ARDS). Alveolar macrophage-derived cytokines contribute to         
the inflammation underlying ARDS, resulting in pulmonary fibrosis and edema, central facets            
of acute lung injury. Plasma lipopolysaccharide (LPS), elevated in obesity, is the key             
component for activation of M1 and a subtype of M2 macrophages (1). ​Chronic M2              
macrophage activation leads to profibrotic mediator production, Transforming Growth         
Factor- β (TGF-β) and Platelet-derived Growth Factor (PDGF) for example, that enhance            
continuous fibroblast activation and myofibroblast proliferation (2). Lung alveolar M2          
macrophages also produce matrix metalloproteinases, MMP7 and MMP9, and their          
overexpression promotes fibrogenesis.  
Here, we hypothesize that alveolar M2 macrophages are activated in response to elevated             
plasma LPS in obese subjects with T2D (OT2D), resulting in excess pro-fibrotic            
inflammatory mediators, and thereby making OT2D patients more vulnerable to          
COVID19-related infection with severe disease. To test our hypothesis, we measured           
circulatory lung alveolar M2 macrophage markers in obese subjects with type 2 diabetes             
(OT2D) and controls. 
A ​parallel study was performed in the Diabetes Research Centre at Hull Royal Infirmary in               
adults with type 2 diabetes (n=23) and nondiabetic controls (n=23). ​The male to female ratio               
of the subjects was similar between cohorts (12 males and 11 females in both control and                
OT2D cohorts). ​The OT2D subjects were older (62​±7 vs 55±10 years, OT2D vs control,              
p<0.0001) ​with a higher BMI ​(32±4 vs 28±3 ​kg/m​2​, OT2D vs control, p<0.0001). ​All              
participants were Caucasian and in the fasting state for 10-hours before venipuncture. ​Slow             
Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement (3) was used to           
determine LPS-binding protein (LPB), TGFβ-1, PDGF-β, MMP7 and MMP9 protein          
concentration expressed as relative fluorescent units (RFU). Statistical analysis was          
performed ​using the Student’s t test ​(GraphPad Prism 8.0​, San Diego, CA).  
LPS-binding (LPB) protein was reduced in plasma (85311.3±1453.1 vs 91746.9±3047.9          
RFU, OT2D vs control, p<0.05). Plasma LPB was also reduced in obese versus non-obese              
subjects regardless of diabetic status (84343.5±1455.7 vs 91398.5±2798.8 RFU, obese vs           
non-obese, p<0.05). Basal levels of TGFβ-1, PDGF-β, MMP7 and MMP9 were significantly            
higher in OT2D versus control: TGFβ-1 (1122.9±72 vs 932.8±27.1 RFU, p<0.01); PDGF-β            
(40610.0±5853.6 vs 25129.0±3271.6 RFU, p<0.05); MMP7 (1241.5±93.4 vs 1004.6±42.0         
RFU, p<0.05) and MMP9 (30192.7±3745.9 vs 19532.3±1562.4 RFU, p<0.05).  
We report here that LPS-related markers were associated with activated lung alveolar M2             
macrophages in OT2D, with a reduction in plasma LPB as a surrogate marker of circulatory               
LPS elevation. ​Previously increased LBP levels were reported in obesity (4, 5), a discrepancy              
compared to our observations might be due to inclusion of obese cases who were smokers               
and alcoholic in those studies. LBP was increased in the bronchoalveolar lavage fluid             
(BALF) of smokers (6). Serum levels of LBP are also increased in heavy drinkers, probably               
reflecting high LPS exposure due to alcohol-induced damage of the gastrointestinal barrier            
(7, 8) However, in our study none of the OT2D subjects were smokers or consumed alcohol,                
as those were exclusion criteria. Moreover, ​LBP, the serum glycoprotein, plays a            
concentration-dependent dual role in determining LPS-induced macrophage activation; low         
concentrations of LBP enhance the LPS-induced activation of mononuclear cells (MNC),           
whereas the acute-phase rise in LBP concentration inhibits LPS-induced cellular stimulation           
(9). ​Furthermore, ​LBP is bound and internalized by host cells and colocalizes with LPS in the                
cytoplasm (10). Therefore, the significantly lower LBP levels reflect the elevated LPS levels             
in OT2D subjects in our study.   
The elevated TGF-β1 shown here may predispose to alveolar pre-fibrosis with their collapse             
following SARS-CoV-2 infection. TGF-β is detected in lung bronchoalveolar lavage fluid of            
90% of patients with ARDS, major cellular sources of TGF-β in pulmonary fibrosis being              
alveolar macrophages and metaplastic type II alveolar epithelial cells. Activation of TGF-β1            
is affected by MMP9 that was elevated here in OT2D, contributing to enhancement of the               
pool of active TGF-β1. MMP9 also weakens the airway epithelia barrier function by altering              
transepithelial electrical conductance and epithelial permeability to macromolecules (11).         
MMP7, also elevated here, is increased in ARDS and associated with idiopathic pulmonary             
fibrosis (IPF), whilst PDGF-β, again elevated here, contributes to fibrosis development with            
TGF-β in ARDS. ​Elevated plasma levels of TGF-β1, PDGF-β, MMP7 and MMP9            
determined early in the course of COVID19 infection in a patient with OT2D may indicate               
potential risk for more severe disease. One limitation of this study is that all participants were                
Caucasian, and the results may not be generalizable to other ethnic groups. ​Moreover, it is               
also possible that, apart from alveolar macrophages, other cellular sources, for example lung             
epithelial cells (12), arterial smooth muscle cells (13), epithelial cells of glandular tissues like              
prostate (14) or bile duct epithelia (15), might contribute to LPS-induced elevated plasma             
levels of those pro-fibrotic markers. 
In conclusion, in OT2D the lung epithelial barrier integrity is likely destabilized in response              
to fibroproliferative activity of elevated TGF-β1, PDGF-β, MMP7 or MMP9 derived from            
lung alveolar macrophages, increasing vulnerability to inhaled pathogens. This might lead to            
irreversible structural alterations and tissue stiffening in the lungs of OT2D patients even             
prior to SARS-COV-2 infection and thereby make these patients more vulnerable to            
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